Figure 4From: The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis Expression of CX3CR1 in the three circulating monocyte subsets examined in patients with RA at baseline and over MTX treatment. Fluorescence intensities (MFI) of CX3CR1 in circulating CD14+highCD16− (panel A), CD14+highCD16+ (panel B) and CD14+lowCD16+ monocytes (panel C) of non-responders (■)and responders (○) at baseline and after 3 and 6 months of MTX treatment, and in healthy controls (▼), are shown as means ± SEM. Panel D is a histogram of CX3CR1 for circulating CD14+highCD16- monocytes from a representative responder and non-responder at 6 months of treatment and their respective isotype controls. *Significant difference between patients and healthy controls. †Significant difference between non-responders and responders. ‡Significant difference between baseline and 6 month values.Back to article page